Erschienen in:
01.07.2014 | Original article
Hypofractionation with simultaneous integrated boost for early breast cancer
Results of the German multicenter phase II trial (ARO-2010-01)
verfasst von:
Kathrin Dellas, MD, Dr. Reinhard Vonthein, Jörg Zimmer, MD, Stefan Dinges, MD, Alexander D. Boicev, MD, Peter Andreas, MD, Dorothea Fischer, MD, Cornelia Winkler, MD, Prof. Dr. Andreas Ziegler, Prof. Jürgen Dunst, MD, ARO Study Group
Erschienen in:
Strahlentherapie und Onkologie
|
Ausgabe 7/2014
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison.
Methods
Eligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22–29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL.
Results
151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99 %) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89 % (95 % CI 82 % to 93 %). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged.
Conclusion
Hypofractionation with a SIB is feasible and was well tolerated in this study.